AMENDMENT #9 TO LIENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc.
Exhibit 10.19
CONFIDENTIAL TREATMENT REQUESTED
Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for confidential treatment.
|
AMENDMENT #9 TO LIENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc. |
THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Master License Agreement entered into and effective as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”) between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte, Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in this Agreement.
WHEREAS, Purdue University continues to develop technologies and scientific advances in the laboratory of Professor Xxxxxx Xxx funded by Endocyte, Inc.; and
WHEREAS, Endocyte wishes to continue licensing such technologies and scientific advances under the Agreement,
NOW THEREFORE, the parties hereto do hereby agree as follows:
|
1. |
The following Elected Eligible Disclosure is added to Schedule A for a Target under Section 1.20(ii): |
|
Title of Elected Eligible Disclosure |
[*] |
|
PRF Reference Number of Elected Eligible Disclosure |
67750 |
|
Contributors of the Elected Eligible Disclosure |
Xxxxxx X. Low and Xxxxx Xxx |
|
2. |
The following Licensed Patents are added to Schedule A of the Agreement for a Target under Section 1.20(ii). |
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
|
PRF Ref # |
Title of Application |
Application Number |
Inventors |
Filing Date |
Country |
Status |
|
67750-01 |
[*] |
[*] |
Xxxxxx X. Low and Xxxxx Xxx |
12/14/2016 |
US (Provisional) |
Filed |
|
67750-02 |
[*] |
[*] |
Xxxxxx X. Low and Xxxxx Xxx |
3/6/2017 |
US (Provisional) |
Filed |
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
Purdue Research FoundationEndocyte, Inc.
By: _/s/ Brooke Beier____________By: _/s/ Xxxx Sherman__________
Name:Xxxxxx Xxxxx Name: Xxxx Xxxxxxx
Title: Executive Director, OTC Title: President & CEO
Date: 11-08-2017 Date: 11-01-17
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
|
AMENDMENT #10 TO LICENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc. |
THIS AMENDMENT, made and entered into this 25th day of August 2017 (“Amendment Effective Date”) amends the Master License Agreement entered into and effective as of July 1, 2013 and all subsequent Amendments (hereinafter “Agreement”) between Purdue Research Foundation (hereinafter known as “PRF”) and Endocyte, Inc. (hereinafter known as “Endocyte”) with respect to the matters addressed in this Agreement.
WHEREAS, Purdue University continues to develop technologies and scientific advances in the laboratory of Professor Xxxxxx Xxx funded by Endocyte, Inc.; and
WHEREAS, Endocyte wishes to continue licensing such technologies and scientific advances under the Agreement,
NOW THEREFORE, the parties hereto do hereby agree as follows:
|
1. |
The following Elected Eligible Disclosure is added to Schedule A of the Agreement for a Target under Section 1.20(ii). |
|
Title of Elected Eligible Disclosure |
|
|
PRF Reference Number of Elected Eligible Disclosure |
67751 |
|
Contributors of the Elected Eligible Disclosure |
Xxxxxx X. Low and Xxxxx Xxx |
|
2. |
The following Licensed Patents are added to Schedule A of the Agreement for a Target under Section 1.20(ii). |
|
PRF Ref # |
Title |
App # |
Inventors |
Filing Date |
Country |
Status |
|
67751-01 |
[*] |
[*] |
Xxxxxx X. Low Xxxxx Xxx |
December 14, 2016 |
US (provisional) |
Filed |
All other terms and conditions of the original agreement remain unchanged and in effect.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Purdue Research FoundationEndocyte, Inc.
By: _/s/ Brooke Beier__________By: _/s/ Xxxx Sherman___________
Name:Xxxxxx Xxxxx Name: Xxxx Xxxxxxx
Title: Executive Director, OTC Title: President & CEO
Date: November 8, 2017 Date: 11-01-17
[*] = Indicates confidential information omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
